Biomarkers with known biological significance in CRC, including TP53 mutations, MSI status and CIN markers such as FGA, aneuploidy score, in addition to the direct PARPi targets—PARP1 and PARP2—were interrogated for their potential utility as PARPi response biomarkers. Here, PARP2 is linked to colorectal carcinoma.